Today (8 August 2019) PHARMAC released a proposal to fund Kadcyla (trastuzumab emtansine, T-DM1) for women with advanced HER2 positive breast cancer.
BCAC media release, 28 July 2019
Breast Cancer Aotearoa Coalition (BCAC) welcomes the announcement that if elected National would set up an independent cancer agency to ensure every New Zealander gets high-quality cancer care and to eliminate post code inequities.
We are thrilled that Lachlan McKenzie (38) has decided to run his first marathon for BCAC. Lachlan’s mum, Julie Bunnell, has advanced breast cancer, and Lachlan is running for BCAC because of the support we give women like her.
UK medicines assessor NICE (National Institute for Health and Care Excellence) has just recommended another combination of drugs for women with advanced hormone-receptor-positive breast cancer. Ribociclib is one of three drugs in the CDK 4/6 inhibitor class, which can extend and improve the lives of women with this type of breast cancer.
Progress continues to be made through world-leading research to identify which treatments will work best for different sub-types of breast cancer.
Breast Cancer Aotearoa Coalition (BCAC) is 100% behind Blair Vining’s petition to Parliament calling for a national cancer agency to address New Zealand’s cancer death rates.
Malaghan Institute media release
In brilliant news, it has been discovered that adding ribociclib to first-line endocrine therapy significantly improves both progression free and overall survival (PFS and OS) for premenopausal women with advanced breast cancer.
The Waikato Breast Cancer Research Trust (WBCRT) is seeking participants with moderately severe treatment-resistant lymphoedema for this research. Is lymphoedema of your arm an ongoing problem for you? Have you undergone at least three months of lymphoedema therapy?
Key findings announced at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago include breakthroughs in the treatment of breast cancer and research. In a series of articles including this one, we outline some of the exciting developments reported.